Skip to content
Lower risk Drug recall · FDA · Published August 20, 2018

Hetero Labs Montelukast Tablets Recalled Due to Blue Specks

Hetero Labs Limited recalls 10mg Montelukast Sodium tablets with blue specks. This may affect prescription medication safety. Stop using and contact your pharmacist.

🇺🇸 FDA recall #D-1213-2018DrugHetero Labs Limited ›
Take action

Contact the company

Recalling firmHetero Labs Limited Unit VUnit V (SEZ Unit I in APIIC SEZ), Surv. No. 439-441, 458, Polepally Vill. · Jadcherla Mandal, Mahaboob Nagar, India
✎ GovInfoNow plain-language explainer

Hetero Labs Limited is recalling 10 mg Montelukast Sodium tablets that have blue specks. This could be a safety issue for people taking prescription asthma medication. Read more at govinfonow.com/recall/39710-hetero-labs-montelukast-tablets-recalled-due-to-blue-specks.

Source Summary by GovInfoNow · govinfonow.com/recall/39710-hetero-labs-montelukast-tablets-recalled-due-to-blue-specks · Updated October 6, 2026 · FDA enforcement record: FDA #D-1213-2018

Cite this page

“Hetero Labs Montelukast Tablets Recalled Due to Blue Specks.” GovInfoNow, updated October 6, 2026. https://govinfonow.com/recall/39710-hetero-labs-montelukast-tablets-recalled-due-to-blue-specks. Based on FDA recall #D-1213-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1213-2018%22&limit=1).

The FDA announced on August 20, 2018, that Hetero Labs Limited Unit V is recalling Montelukast Sodium Tablets due to blue specks found on the tablets. Owners should stop using the product and contact the company for a refund. The recall affects 98,016 bottles distributed nationwide.

How to tell if you have it

  • Brand: Hetero Labs Limited
  • Product: Montelukast Sodium Tablets, 10 mg*, 30-count bottles, Rx Only
  • Manufacturer: Hetero, Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahaboob Nagar - 509 301, India
  • Distributed for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854
  • NDC: 31722-726-30
  • Lot #: MON17355
  • Expiration Date: 12/19
  • Quantity: 98,016 bottles
  • Distribution: Nationwide in the USA

The hazard

The hazard is discoloration, specifically blue specks on the tablets. The FDA stated that a complaint was received from a pharmacist regarding this issue.

Context

GovInfoNow's records show Hetero Labs Limited (Unit V) has had six other recalls since December 22, 2017. Other recent recalls of similar products include Hetero Labs Pantoprazole Tablets Recall (March 26, 2026), Hetero Labs Losartan Tablets Recall (August 6, 2020), and Hetero Labs Montelukast Tablets Recall (August 15, 2018). Other recent recalls of similar products include Sun Pharmaceutical Carbamazepine Tablets Recall (August 3, 2026), Golden State Medical Supply recalls Carbamazepine 200mg tablets (August 7, 2026), and Guardian Drug Goodsense Ultra Strength Antacid Tablets Recall (May 28, 2026).

How to tell if you have this one

Check for 10 mg Montelukast Sodium tablets with blue specks. The product was sold in India by Hetero Labs Limited, Unit V, with NDC 31722-726-30.

  • Brand
    Hetero Labs Limited
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check for Blue Specks

    Look for blue specks on the tablets. If present, stop using the product.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 3.2 years after the firm started it.

1. Firm started the recall: Aug 20, 201812. FDA classified it Class II: Sep 26, 201823. Published in FDA’s Enforcement Report: Oct 3, 201834. FDA terminated the recall: Nov 5, 2021420182021
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1213-2018 (August 20, 2018) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1213-2018 to see it in context.
  • Plain-language summary written by qwen3:4b on October 6, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA